Oaktree Acquisition Corp. III Life Sciences
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
OACC$10.70-0.2%Stored close · as of Nov 5, 2026
Contents
Statement of Operations
| General and administrative expenses | $351,806 |
|---|---|
| Loss from operations | (351,806) |
| Other income | |
| Change in fair value of overallotment liability | 94,781 |
| Interest earned on cash held in Trust Account | 1,588,732 |
| Total other income | 1,683,513 |
| Net income | $1,331,707 |
| Weighted average shares outstanding of redeemable Class A ordinary shares | 6,776,020 |
| Basic and diluted net income per ordinary share, redeemable Class A ordinary shares | $0.12 |
| Weighted average shares outstanding of non-redeemable Class A and B ordinary shares | 4,701,459 |
| Basic net income per ordinary share, non-redeemable Class A ordinary shares and Class B ordinary shares | $0.12 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.